Legend Biotech Highlights Submission Of New Drug Application To Japanese Regulatory Authority For B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor-T Cell Therapy For Treatment Of Adults With Relapsed, Refractory Multiple Myeloma